+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Global Cardiac Biomarker Market (2021-2026) by Product, Type, Location of Testing, Application, Geography, Competitive Analysis and the Impact of Covid-19 with Ansoff Analysis

  • PDF Icon

    Report

  • 187 Pages
  • June 2021
  • Region: Global
  • Infogence Global Research
  • ID: 5410393
The Global Cardiac Biomarker Market is estimated to be USD 3.71 Bn in 2021 and is expected to reach USD 6.99 Bn by 2026, growing at a CAGR of 13. 52%.



Market Dynamics

The factors such as the rise in the number of patients suffering from Acute Coronary Syndrome ACS, the unique features of cardiac biomarker such as showing high accuracy, quick outcomes, and economical pricing of cardiac point of care (POC) testing, and the growing awareness among patients and healthcare providers about the importance of early diagnosis and care of various CVDs is driving the demand for these markers. In addition, the rise in investment in research and development activities by various public and private institutions for the development of advanced technologies in the field of the global cardiac biomarker market is expected to create more opportunities for the growth of the market.

However, the cardiac biomarkers market is facing restraints in the growth of the market due to the development of other methods for diagnosis of cardiovascular diseases, along with the high cost involved in the procedure of cardiac biomarker, lack of full proof assurance, and steep competition among existing players dealing with cardiac biomarker.

Market Segmentation

The Global Cardiac Biomarker Market is segmented further based on Product, Type, Location of Testing, Application, and Geography.

By Product, the market is classified as Reagents & Kits and Instruments. Amongst the two, the Instrument segment is estimated to hold the highest market share during the forecast period.

By Type, the market is classified into Myocardial Muscle Creatine Kinase (CK-MB), Troponins, Myoglobin, Brain Natriuretic Peptide (BNPS), HSCRP, and Others. Amongst all, Troponins segment is estimated to hold the highest market share during the forecast period.

By Location of Testing, the market is classified as Laboratory Testing and Point of Care Testing. Amongst all, Laboratory Testing segment is estimated to hold the highest market share during the forecast period.

By Application, the market is classified as Myocardial Infarction, Congestive Heart Failure, Acute Coronary Syndrome, Atherosclerosis, and Others. Amongst all, Acute Coronary Syndrome segment is estimated to hold the highest market share during the forecast period.

By Geography, North America is projected to lead the market.

Recent Developments

1. Roche announces five new intended uses for key cardiac biomarkers to help identify cardiovascular risk, better diagnose patients and support early treatment - 28th April 2021

Company Profiles

Some of the companies covered in this report are Abbott Laboratories, Beckman Coulter, Inc. bioMérieux SA, Johnson and Johnson, Olympus Corporation, etc.

Competitive Quadrant

The report includes Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Why buy this report?

  • The report offers a comprehensive evaluation of the Global Cardiac Biomarker Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.
  • The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel in the industry.
  • The report includes an in-depth market analysis using Porter’s 5 forces model and the Ansoff Matrix. In addition, the impact of Covid-19 on the market is also featured in the report.
  • The report also includes the regulatory scenario in the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules and regulations imposed on this sector across various geographies.
  • The report also contains the competitive analysis using Positioning Quadrants, the analyst’s Proprietary competitive positioning tool.

Report Highlights:

  • A complete analysis of the market, including parent industry
  • Important market dynamics and trends
  • Market segmentation
  • Historical, current, and projected size of the market based on value and volume
  • Market shares and strategies of key players
  • Recommendations to companies for strengthening their foothold in the market
Frequently Asked Questions about the Global Cardiac Biomarker Market

What is the estimated value of the Global Cardiac Biomarker Market?

The Global Cardiac Biomarker Market was estimated to be valued at $3710 Million in 2021.

What is the growth rate of the Global Cardiac Biomarker Market?

The growth rate of the Global Cardiac Biomarker Market is 13.5%, with an estimated value of $6990 Million by 2026.

What is the forecasted size of the Global Cardiac Biomarker Market?

The Global Cardiac Biomarker Market is estimated to be worth $6990 Million by 2026.

Who are the key companies in the Global Cardiac Biomarker Market?

Key companies in the Global Cardiac Biomarker Market include Abbott Laboratories, Advanced ImmunoChemical, AgPlus Diagnostics, Alere Inc, Beckman Coulter, Inc., Becton Dickinson and Co, BG Medicine, BioLegend and Bio.

Table of Contents

1 Report Description
1.1 Study Objectives
1.2 Market Definition
1.3 Currency
1.4 Years Considered
1.5 Language
1.6 Key Stakeholders
2 Research Methodology
2.1 Research Process
2.2 Data Collection and Validation
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Models
2.3 Market Size Estimation
2.3.1 Bottom-Up Approach
2.3.2 Top-Down Approach
2.4 Assumptions of the Study
2.5 Limitations of the Study
3 Executive Summary
3.1 Introduction
3.2 Market Size and Segmentation
3.3 Market Outlook
4 Market Influencers
4.1 Drivers
4.1.1 Increasing Prevalence of Cardiovascular Diseases
4.1.2 Growing Awareness for the Need for Early Diagnosis of Cardiovascular Diseases
4.2 Restraints
4.2.1 Issue Related to Sample Collection and Storage
4.2.2 Strict Government Regulations and Policies
4.3 Opportunities
4.3.1 Point-Of-Care Testing (POCT) with Cardiac Biomarkers
4.3.2 Increasing Funding in Research and Development Activities
4.4 Challenges
4.4.1 Concerns Across Regulatory and Reimbursement Systems
4.5 Trends
5 Market Analysis
5.1 Regulatory Scenario
5.2 Porter’s Five Forces Analysis
5.3 Impact of COVID-19
5.4 Ansoff Matrix Analysis
6 Global Cardiac Biomarker Market, By Product
6.1 Introduction
6.2 Reagents & Kits
6.3 Instruments
6.3.1 Immunofluorescence
6.3.2 ELISA
6.3.3 Immunochromatography
6.3.4 Chemiluminescence
7 Global Cardiac Biomarker Market, By Type
7.1 Introduction
7.2 Myocardial Muscle Creatine Kinase (CK-MB)
7.3 Troponins
7.4 Myoglobin
7.5 Brain Natriuretic Peptide (BNPs)
7.6 HSCRP
7.7 Others
8 Global Cardiac Biomarker Market, By Location of Testing
8.1 Introduction
8.2 Laboratory Testing
8.3 Point of Care Testing
9 Global Cardiac Biomarker Market, By Application
9.1 Introduction
9.2 Myocardial Infarction
9.3 Congestive Heart Failure
9.4 Acute Coronary Syndrome
9.5 Atherosclerosis
9.6 Others
10 Global Cardiac Biomarker Market, By Geography
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.2.3 Mexico
10.3 South America
10.3.1 Brazil
10.3.2 Argentina
10.3.3 Chile
10.3.4 Colombia
10.4 Europe
10.4.1 UK
10.4.2 France
10.4.3 Germany
10.4.4 Italy
10.4.5 Spain
10.4.6 Netherlands
10.4.7 Sweden
10.4.8 Russia
10.4.9 Rest of Europe
10.5 Asia-Pacific
10.5.1 China
10.5.2 Japan
10.5.3 India
10.5.4 Indonesia
10.5.5 Malaysia
10.5.6 South Korea
10.5.7 Australia
10.5.8 Sri Lanka
10.5.9 Thailand
10.5.10 Rest of APAC
10.6 Middle-East and Africa
10.6.1 Qatar
10.6.2 Saudi Arabia
10.6.3 South Africa
10.6.4 United Arab Emirates
11 Competitive Landscape
11.1 Competitive Quadrant
11.2 Market Share Analysis
11.3 Strategic Initiatives
11.3.1 M&A and Investments
11.3.2 Partnerships and Collaborations
11.3.3 Product Developments and Improvements
12 Company Profiles
12.1 Abbott Laboratories
12.2 Advanced ImmunoChemical
12.3 AgPlus Diagnostics
12.4 Alere Inc
12.5 Beckman Coulter, Inc.
12.6 Becton Dickinson and Co
12.7 BG Medicine
12.8 BioLegend
12.9 BioMerieux
12.10 Bio-Rad Laboratories, Inc.
12.11 BODITECH MED
12.12 Dickinson and Company
12.13 F. Hoffmann-La Roche Ltd.
12.14 Johnson and Johnson
12.15 Olympus Corporation
12.16 PerkinElmer Inc.
12.17 Randox Laboratories Ltd.
12.18 Roche Diagnostics Corporation
12.19 Siemens Healthcare
12.20 Thermo Fisher Scientific
12.21 Tosoh Corporation
13 Appendix
13.1 Questionnaire

Companies Mentioned

  • Abbott Laboratories
  • Advanced ImmunoChemical
  • AgPlus Diagnostics
  • Alere Inc
  • Beckman Coulter, Inc.
  • Becton Dickinson and Co
  • BG Medicine
  • BioLegend
  • BioMerieux
  • Bio-Rad Laboratories, Inc.
  • BODITECH MED
  • Dickinson and Company
  • F. Hoffmann-La Roche Ltd.
  • Johnson and Johnson
  • Olympus Corporation
  • PerkinElmer Inc.
  • Randox Laboratories Ltd.
  • Roche Diagnostics Corporation
  • Siemens Healthcare
  • Thermo Fisher Scientific
  • Tosoh Corporation